switching from semaglutide to zepbound Tirzepatide: A Provider's Guide Does a patient on 1.7 Wegovy® vs. Zepbound®: Kevin Lost

Metagenome analysis of intestinal bacteria in healthy people, patients with inflammatory bowel disease and colorectal cancer

Gastrointestinal Adverse Events GI AEs are the most frequently reported side effects of GLP-1 RAs and, although typically mild, moderate, and transient, they remain the primary reason for treatment discontinuation among individuals with obesity receiving semaglutide [13, 27, 38, 40,41,42,43,44,45,46, 52]

[DOI] [PMC free article] [PubMed] [Google Scholar] Zheng M

Provider experience with tirzepatide is important, as appropriate dose titration and side effect management require familiarity with the medication

European Review for Medical and Pharmacological Sciences, 2013

Not only is this behavior reckless for consumers, but it is also detrimental to the business models of the med spas and telehealth services that use Groupon for distribution, as these businesses only offer these Groupon trials as lead generation to convert customers into higher margin recurring revenue streams